BC Extra | Sep 25, 2019
Politics & Policy

Additional price cuts in nationwide expansion of China’s centralized procurement

China’s Joint Procurement Office announced steep price cuts for companies that won the tender bids for 25 drugs in the nationwide expansion of its pilot program for centralized procurement of generic and off-patent originator drugs....
BC Extra | Sep 12, 2018
Politics & Policy

China biopharma stocks fall after centralized tendering talks

Stocks of Chinese biopharma companies slid on Wednesday, possibly in response to a meeting Tuesday of China's National Medical Insurance Bureau on the centralized procurement of generics. Under centralized procurement, a single generic manufacturer would...
BioCentury | Apr 6, 2018

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
BioCentury | Jan 6, 2018

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Nov 30, 2017
Clinical News

FDA accepts NDA for Kitov's KIT-302 to treat OA pain and hypertension

FDA accepted for review an NDA from Kitov Pharmaceuticals Holdings Ltd. (Tel Aviv:KTOV; NASDAQ:KTOV) for celecoxib/amlodipine besylate (KIT-302) to treat pain associated with osteoarthritis and hypertension simultaneously. The PDUFA date is May 31. The candidate...
BC Extra | Nov 22, 2017
Clinical News

Researchers use RWE to reproduce trial results

In an article published in the Journal of the American Medical Association, a team of Harvard researchers used real-world evidence from a U.S. health insurance database to replicate the results of a randomized clinical trial...
BC Week In Review | Mar 17, 2017
Company News

Kitov, Kuhnil deal

Kitov granted Kuhnil exclusive South Korean rights to develop and commercialize KIT-302 . Kitov is eligible for undisclosed regulatory milestones and double-digit royalties. Kuhnil will be responsible for obtaining regulatory approval in South Korea and expects...
BC Innovations | Jan 3, 2017
Distillery Therapeutics


INDICATION: Breast cancer; pancreatic cancer Patient sample and mouse studies suggest inhibiting CACNA1D or CACNA1S could help treat invasive breast and pancreatic cancers. In patients with invasive breast cancer, levels of CACNA1D were higher in...
BC Week In Review | Jul 25, 2016
Clinical News

Celecoxib/amlodipine besylate: Additional Phase III data

Additional data from a double-blind, placebo-controlled, U.K. Phase III trial in 152 patients with hypertension showed that once-daily oral 200 mg celecoxib/10 mg amlodipine besylate for 2 weeks reduced serum creatinine levels by 3.22 umol/L...
BC Week In Review | Apr 18, 2016
Company News

Epic Pharma, Humanwell Healthcare Group, PuraCap Pharmaceutical LLC deal

Humanwell and PuraCap will acquire generic company Epic for $550 million. Epic’s assets include generics of cardiovascular drug amlodipine, marketed as Norvasc by Pfizer Inc. (NYSE:PFE, New York, N.Y.); depression drug citalopram, marketed as Celexa...
Items per page:
1 - 10 of 214